| Literature DB >> 33615243 |
Kamali A Thompson1, David Klein1, Michael J Alaia1, Eric J Strauss1, Laith M Jazrawi1, Kirk A Campbell1.
Abstract
PURPOSE: To evaluate the efficacy of oral nonsteroidal anti-inflammatory drugs (NSAIDs) as the primary postoperative pain medication compared with standard oral opioids after arthroscopic shoulder capsulolabral (Bankart) repair for recurrent anterior shoulder instability.Entities:
Year: 2020 PMID: 33615243 PMCID: PMC7879172 DOI: 10.1016/j.asmr.2020.08.003
Source DB: PubMed Journal: Arthrosc Sports Med Rehabil ISSN: 2666-061X
Fig 1Consort diagram (Consort Transparent Reporting of Trials).
Patient characteristics
| Characteristic | NSAID Group (n = 40) | Opioid-Only Group (n = 40) | |
|---|---|---|---|
| Age (y) | 29.9 ± 10.1 | 32.6 ± 10.8 | .25 |
| Body mass index (kg/m2) | 24.8 ± 5.9 | 25.4 ± 3.9 | .62 |
| Sex | |||
| Female | 13 (32.5) | 15 (37.5) | .64 |
| Male | 27 (67.5) | 25 (62.5) | .64 |
| Smoking | |||
| Nonsmoker | 32 (80) | 32 (80) | 1.0 |
| Former smoker | 4 (10) | 4 (10) | 1.0 |
| Smoker | 4 (10) | 4 (10) | 1.0 |
| Anchors | 3.5 ± 1.1 | 3.3 ± 1.1 | .53 |
| Concomitant procedure | |||
| Total patients | 15 | 21 | .18 |
| Labral debridement | 10 | 6 | .26 |
| Rotator cuff debridement | 3 | 11 | .01 |
| Rotator cuff repair | 1 | 1 | 1.0 |
| Subacromial decompression | 7 | 8 | .77 |
| Biceps tenodesis | 3 | 7 | .17 |
| Acromioplasty | 6 | 10 | .26 |
| Distal clavicle resection | 5 | 8 | .36 |
| Bursectomy | 5 | 8 | .36 |
| Synovectomy | 4 | 6 | .50 |
| Remplissage | 1 | 1 | 1.0 |
| Loose body removal | 2 | 0 | .15 |
Data are mean ± standard deviation, n (%), or n.
NSAID, nonsteroidal anti-inflammatory drug.
Postoperative pain and medication consumption
| Factor | NSAID Group (n = 40) | Opioid-Only Group (n = 40) | |
|---|---|---|---|
| VAS score | |||
| 24 h | 5.8 ± 2.3 | 5.4 ± 2.8 | .47 |
| 96 h | 4.0 ± 2.3 | 3.8 ± 2.3 | .72 |
| 1 wk | 2.7 ± 1.7 | 2.7 ± 1.9 | 1.00 |
| Opioid consumption (no. of tablets) | |||
| POD 0 to 1 | 3.3 ± 3.0 | 3.9 ± 2.3 | .35 |
| POD 2 to 4 | 2.9 ± 3.3 | 5.5 ± 5.2 | .05 |
| POD 5 to 7 | 1.4 ± 2.6 | 2.5 ± 5.2 | .23 |
| Total consumed | 7.9 ± 6.9 | 11.7 ± 10.8 | .05 |
| NSAID consumption (no of tablets) | |||
| PODs 0 to 1 | 3.2 ± 2.5 | 1.7 ± 3.6 | .05 |
| PODs 2 to 4 | 7.3 ± 5.1 | 3.6 ± 6.1 | .01 |
| PODs 5 to 7 | 5.0 ± 4.7 | 2.8 ± 4.4 | .05 |
| Total consumed | 15.4 ± 10.4 | 7.8 ± 11.8 | .001 |
| Patient satisfaction at 1 wk | 9.0 ± 1.0 | 8.6 ± 1.8 | .26 |
Data are mean ± standard deviation.
NSAID, nonsteroidal anti-inflammatory drug; POD, postoperative drug.
Adverse effects experienced POD 0-7
| Effect | PODs 0 to 1 | PODs 2 to 4 | POD 5 to 7 |
|---|---|---|---|
| NSAID group | |||
| Nausea | 2 | 0 | 0 |
| Nausea and vomiting | 2 | 0 | 0 |
| Constipation | 0 | 3 | 2 |
| Opioid group | |||
| Nausea | 3 | 2 | 0 |
| Nausea and vomiting | 2 | 0 | 0 |
| Vomiting | 2 | 2 | 0 |
| Constipation | 4 | 3 | 3 |
Data are n.
NSAID, nonsteroidal anti-inflammatory drug; POD, postoperative day.